drugset / Trial / NCT04393220
Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The aie of this clinical study is the safety and efficacy of combination therapy for HCC patients.
Timeline
- Start
- 2020-05-11
- Primary completion
- 2021-07-30
- Completion
- 2021-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
Indications
No indication recorded.